Mobile Video Conferencing

Video Conferencing An Inflection Point

*Apple Facetime 3G only for iOS 6 on iPhone 4S, iPhone 5, new iPad 3, iPad 4, iPad mini, best video quality with hardware DSP acceleration
Google+ Hangouts using Vidyo H.264 SVC
ooVoo comparison
fring Dynamic Video Quality
FriendCaller
*skype SD VP8, HD H264, audio from G.729 to SVOPC to SILK
*Tango
WeChat 微信
Camfrog 
VPHO
VSir 千里眼视频通信
eSky.co

Vidyo Mobile with other vidyo devices, 480x270 encoding, 720p decoding, H264 Scalable Video Coding, Speex wideband audio codec 32kbps

Google Voice no iPad, video chat only on PC, H264
qik video only on certain mobile phones

Video Conferencing on PC

Viber using Spirit DSP no video

Full-HD Voice: Understanding the AAC codecs behind a new era in communication AAC Enhanced Low Delay v2
AAC-ELD > Opus (CELT+SILK) > CELT (ogg, low latency) > G.719 (Polycom) > AAC-LD > SILK (Skype, speech) > G722.2 (AMR-WB) > Speex

Audio/Video Files, Codecs and Containers

Medical facilities, departments, healthcare professionals, and specialties

ABMS specialty American Board of Medical Specialties, ABMS Guide to Medical Specialties

ABMS Board Certification Report

General Certificate(s)	Subspecialty Certificates
American Board of Allergy and Immunology
Allergy and Immunology	No Subspecialties
American Board of Anesthesiology
Anesthesiology	Critical Care Medicine Hospice and Palliative Medicine Pain Medicine Pediatric Anesthesiology Sleep Medicine
American Board of Colon and Rectal Surgery
Colon and Rectal Surgery	No Subspecialties
American Board of Dermatology
Dermatology	Dermatopathology Pediatric Dermatology
American Board of Emergency Medicine
Emergency Medicine	Anesthesiology Critical Care Medicine1 Emergency Medical Services Hospice and Palliative Medicine Internal Medicine-Critical Care Medicine Medical Toxicology Pain Medicine Pediatric Emergency Medicine Sports Medicine Undersea and Hyperbaric Medicine
American Board of Family Medicine
Family Medicine	Adolescent Medicine Geriatric Medicine Hospice and Palliative Medicine Pain Medicine Sleep Medicine Sports Medicine
American Board of Internal Medicine
Internal Medicine	Adolescent Medicine Adult Congenital Heart Disease2 Advanced Heart Failure and Transplant     Cardiology Cardiovascular Disease Clinical Cardiac Electrophysiology Critical Care Medicine Endocrinology, Diabetes and Metabolism Gastroenterology Geriatric Medicine Hematology Hospice and Palliative Medicine Infectious Disease Interventional Cardiology Medical Oncology Nephrology Pulmonary Disease Rheumatology Sleep Medicine Sports Medicine Transplant Hepatology
American Board of Medical Genetics
Clinical Biochemical Genetics* Clinical Cytogenetics* Clinical Genetics (MD)* Clinical Molecular Genetics*	Medical Biochemical Genetics Molecular Genetic Pathology
American Board of Neurological Surgery
Neurological Surgery	No Subspecialties
American Board of Nuclear Medicine
Nuclear Medicine	No Subspecialties
American Board of Obstetrics and Gynecology
Obstetrics and Gynecology	Critical Care Medicine Female Pelvic Medicine and      Reconstructive Surgery Gynecologic Oncology Hospice and Palliative Medicine Maternal and Fetal Medicine Reproductive Endocrinology/Infertility
American Board of Ophthalmology
Ophthalmology	No Subspecialties
American Board of Orthopaedic Surgery
Orthopaedic Surgery	Orthopaedic Sports Medicine Surgery of the Hand
American Board of Otolaryngology
Otolaryngology	Neurotology Pediatric Otolaryngology Plastic Surgery Within the Head and Neck Sleep Medicine
American Board of Pathology
Pathology-Anatomic/Pathology-Clinical* Pathology - Anatomic* Pathology - Clinical*	Blood Banking/Transfusion Medicine Clinical Informatics Cytopathology Dermatopathology Neuropathology Pathology - Chemical Pathology - Forensic Pathology - Hematology Pathology - Medical Microbiology Pathology - Molecular Genetic Pathology - Pediatric
American Board of Pediatrics
Pediatrics	Adolescent Medicine Child Abuse Pediatrics Developmental-Behavioral Pediatrics Hospice and Palliative Medicine Medical Toxicology Neonatal-Perinatal Medicine Pediatric Cardiology Pediatric Critical Care Medicine Pediatric Emergency Medicine Pediatric Endocrinology Pediatric Gastroenterology Pediatric Hematology-Oncology Pediatric Infectious Diseases Pediatric Nephrology Pediatric Pulmonology Pediatric Rheumatology Pediatric Transplant Hepatology Sleep Medicine Sports Medicine
American Board of Physical Medicine and Rehabilitation
Physical Medicine and Rehabilitation	Brain Injury Medicine3 Hospice and Palliative Medicine Neuromuscular Medicine Pain Medicine Pediatric Rehabilitation Medicine Spinal Cord Injury Medicine Sports Medicine
American Board of Plastic Surgery
Plastic Surgery	Plastic Surgery Within the Head and Neck Surgery of the Hand
American Board of Preventive Medicine
Aerospace Medicine* Occupational Medicine* Public Health and General Preventive Medicine*	Clinical Informatics Medical Toxicology Undersea and Hyperbaric Medicine
American Board of Psychiatry and Neurology
Psychiatry* Neurology* Neurology with Special Qualification      in Child Neurology*	Addiction Psychiatry Brain Injury Medicine3 Child and Adolescent Psychiatry Clinical Neurophysiology Epilepsy Forensic Psychiatry Geriatric Psychiatry Hospice and Palliative Medicine Neurodevelopmental Disabilities Neuromuscular Medicine Pain Medicine Psychosomatic Medicine Sleep Medicine Vascular Neurology
American Board of Radiology
Diagnostic Radiology* Interventional Radiology and Diagnostic Radiology*3 Radiation Oncology* Medical Physics*	Hospice and Palliative Medicine Neuroradiology Nuclear Radiology Pain Medicine Pediatric Radiology Vascular and Interventional Radiology
American Board of Surgery
Surgery* Vascular Surgery*	Complex General Surgical Oncology4 Hospice and Palliative Medicine Pediatric Surgery Surgery of the Hand Surgical Critical Care
American Board of Thoracic Surgery
Thoracic and Cardiac Surgery	Congenital Cardiac Surgery
American Board of Urology
Urology	Female Pelvic Medicine and      Reconstructive Surgery Pediatric Urology

*Specific disciplines within the specialty where certification is offered. 1Approved 2013; first issue 2014 2Approved 2012; first issue to be determined 3Approved 2011; first issue 2014 4Approved 2011; first issue to be determined   Residency (PGY), Attending physician  見習 Clerk 實習 Intern 住院 Resident 總住院 CR 研究醫師 Fellow 主治 VS 主任 Chief   National Resident Matching Program: Main Residency Match Data & Reports PGY, Residence, Fellowship, 2015 Advance Data Tables: Main Residency Match Residency Length Transitional/Preliminary: 1 year Emergency Medicine: 3-4 years Family Practice: 3 years Internal Medicine: 3 years Pediatrics: 3 years Obstetrics-Gynecology: 4 years Pathology: 4 years Psychiatry: 4 years Anesthesiology: 3 years plus PGY-1 Transitional/Preliminary Dermatology: 3 years plus PGY-1 Transitional/Preliminary Neurology: 3 years plus PGY-1 Transitional/Preliminary Opthamology: 3 years plus PGY-1 Transitional/Preliminary Physical Medicine: 3 years plus PGY-1 Transitional/Preliminary Diagnostic Radiology: 4 years plus PGY-1 Transitional/Preliminary Radiation Oncology: 4 years plus PGY-1 Transitional/Preliminary General Surgery: 5 years Orthopaeic Surgery:  5 years (includes 1 year of general surgery) Otolaryngology: 5 years (includes 1 year of general surgery) Plastic Surgery: 5-6 years (includes 1 year of general surgery) Neurological Surgery: 6 years (includes 1 year of general surgery) 台灣 行政院 衛生福利部＞前往本部各單位＞醫事司＞醫院評鑑資訊公開  Taiwan Hospital Review

健保局 > 一般民眾 > 健保醫療服務 > 健保特約醫事機構查詢 醫學中心, 區域醫院, 地區醫院, 診所 Taiwan Health Insurance Medical Centers, Hospitals, Clinics

財團法人醫院評鑑暨醫療品質策進會: 行政院衛生署97-100年度新制醫院評鑑及新制教學醫院評鑑合格名單

醫療資源暨地理資訊查詢 Taiwan Medical Resource GIS

台北市立萬芳醫院－委託財團法人私立臺北醫學大學辦理 Taipei WanFang Hospital

家庭醫學科	Family Medicine	內科	Internal Medicine
外科	Surgery	小兒科	Pediatrics
婦產科	Obstetrics and Gynecology	骨科	Orthopaedic Surgery
神經科	Neurology	神經外科	Neurological Surgery
泌尿科	Urology	耳鼻喉科	Otolaryngology
眼科	Ophthalmology	皮膚科	Dermatology
精神科	Psychiatry	復健科	Physical Medicine and Rehabilitation
麻醉科	Anesthesiology	放射線科(診斷)	Diagnostic Radiology
放射線科(腫瘤)	Radiation Oncology	放射線科(核醫)	Nuclear Medicine
病理科(解剖)	Pathology-Anatomic	病理科(臨床)	Pathology-Clinical
核子醫學科	Nuclear Medicine	急診醫學科	Emergency Medicine
整形外科	Plastic Surgery	職業醫學科	Occupational Medicine
一般科	General	其他	Other
牙科	Dentistry	口腔病理科	Oral Pathology
口腔顎面外科	Oral and Maxillofacial Surgery	中醫	Traditional Chinese Medicine

語言治療師	Speech Therapist	牙體技術師	Dental Technologist
聽力師	Audiologist	牙體技術生	Dental Technician
西醫師	Physician	中醫師	Traditional Chinese Physician
牙醫師	Dentist	藥師	Pharmacist
藥劑生	Pharmacy Assistant	護理師	Registered Nurse
護士	Nursing Assistant	助產士	Mid-wife
助產師	Nurse Mid-wife	醫事檢驗師	Medical and Clinical Technologist
醫事檢驗生	Medical and Clinical Technician	鑲牙生	0
中藥員	0	齒模員	0
非醫事人員	Non-Medical	接骨員	0
物理治療師	Physical Therapist	職能治療師	Occupational Therapist
醫事放射師	Radiology Technologist	醫事放射士	Radiology Technician
物理治療生	PT Assistant	呼吸治療師	Respiratory Therapist
職能治療生	OT Assistant	諮商心理師	Counseling Psychologist
臨床心理師	Clinical Psychologist	營養師	Nutritionist

行政院衛生署 專科醫師制度
歷年專科醫師核證人數


臺灣醫學會 專科醫學會
中華民國醫師公會全國聯合會 專科醫學會

家庭醫學科 台灣家庭醫學醫學會
內科 台灣內科醫學會
外科 台灣外科醫學會
小兒科 臺灣兒科醫學會
婦產科 台灣婦產科醫學會
骨科 中華民國骨科醫學會
神經外科 台灣神經外科醫學會
泌尿科 台灣泌尿科醫學會
耳鼻喉科 台灣耳鼻喉科醫學會
眼科 中華民國眼科醫學會
皮膚科 臺灣皮膚科醫學會
神經科 台灣精神醫學會
精神科 台灣神經學學會
復健科 台灣復健醫學會
麻醉科 台灣麻醉醫學會
放射線(診斷)科 中華民國放射線醫學會
放射線(腫瘤)科 台灣放射腫瘤學會
病理(解剖)科 台灣病理學會
病理(臨床)科 台灣臨床病理檢驗醫學會
核子醫學科 中華民國核醫學學會
整形外科 台灣整形外科醫學會
急診醫學科 台灣急診醫學會
職業醫學科 中華民國環境職業醫學會

牙醫 中華牙醫學會
口腔顎面外科 中華民國口腔顎面外科學會
口腔病理科 中華民國口腔病理學會

European Union of Medical Specialists

UEMS Specialist Sections

Allergology
Anaesthesiology
Cardiology
Cardiothoracic Surgery
Child and Adolescent Psychiatry and Psychotherapy
Clinical Neurophysiology
Dermatology and Venereology
Emergency Medicine
Endocrinology
Gastroenterology
Geriatrics
Gynaecology and Obstetrics
Infectious Diseases
Internal Medicine
Laboratory Medicine / Medical Biopathology
Medical Microbiology
Nephrology
Neurology
Neurosurgery
Nuclear Medicine
Occupational Medicine
Ophthalmology
Oro-Maxillo-Facial Surgery / Stomatology
Orthopaedics
Otorhinolaryngology
Paediatric Surgery
Paediatrics
Pathology
Physical Medicine and Rehabilitation
Plastic, Reconstructive and Aesthetic Surgery
Pneumology
Psychiatry
Public Health Medicine
Radiology
Radiotherapy
Rheumatology
Surgery
Urology
Vascular Surgery

Multidisciplinary Joint Committee

Clinical Genetics
Emergency Medicine
Hand Surgery
Immune Mediated Disease
Intensive Care Medicine
Oncology
Pain Medicine
Paediatric Urology 
Sexual Medicine
Spine Surgery
Sports Medicine 

Elderly care

Taiwan Population Pyramid 

Elder care elder old 
Long-term_care 
Independent living 安養 
Assisted living 養護 
Nursing home 護理之家 長期照護 

Hospice 

Adult daycare center 日照  

Retirement community 

Aging in place 
Continuing care retirement communities (CCRC) 多層級 連續性 

Program of All-Inclusive Care for the Elderly PACE - nursing home eligible

銀髮族如何安居？ 新老社會來了 Taiwan 

安老新趨勢-高齡友善住宅百花齊放 公私齊力落實社區共融 

照顧攏抵家：結合生活服務與醫養照顧　開啟養生住宅新紀元 

三芝 雙連安養中心 連續性照顧, 雙連安養中心前執行長蔡芳文 

* 台北市至善老人安養護中心, 天主教永和耕莘醫院 65, 至善老人安養護中心簡介 

淡水 潤福生活新象 中高齡專用住宅 50 

日勝生集團 - 日初不老莊園 

* 樂陶居 中和舘 55 

新竹 一里雲村 金色天地安養中心 

新竹 明新敬老中心 頤養園國際養生智能園區 

太平榮家 - 台東縣樂齡健康長照園區, 台東基督教醫院

台灣安養中心指南 

長照銀髮住宅觀察站 

橘世代 退休想住養生村？2023全台6大養生村費用、房型比較一次看(含表格) 

50+ 老後想住養老院，一個月要花多少錢？全台5家養生村、樂齡宅特色與費用一覽 

潤福新象 康寧生活會館 長庚養生村 樂陶居

臺北市文山區養護機構 安養機構 
台北市政府社會局 銀髮族服務 福利據點 
台北市老人安養暨長期照顧機構一覽表 - 安養院 養護中心 長照 日照 
新北市政府社會局 失能老人日間照顧（護） 
中華民國老人福利推動聯盟 日間照顧縣市資源搜尋 
內政部 99年度老人福利機構評鑑成績 

臺北市政府社會局老人自費安養中心 Senior Homes, retirement housing 
台北市兆如老人安養護中心 安養 養護 長照 日照 
臺北市文山老人養護中心 養護 日照 
Maps 

台灣長期照護專業協會 如何選擇合適的照護 選擇機構三大原則 

台北市政府衛生局長期照顧資訊網 
行政院衛生署 護理及健康照護處 一般護理之家評鑑專區 
行政院衛生署 醫療資源 進階查詢 -> 護理機構 -> 護理之家 
老人福利機構與護理之家功能比較表 

California AB567 Long Term Care Insurance Task Force LTC FAQ AB-567 
WA Cares Fund $36,500 ($0.58/$100 for 10 years) 
Who is Caring for WA Cares? Part 1: Deductions to Start July 1, 2023, WA Cares 7/1/2023 

Cancer Clinical Trials

Women's Cancer Network Clinical Trials Gynecologic Oncology Group (GOG) Trials - incomplete
My Clinical Trial Locator: map

National Cancer Institute (NCI) Clinical Trials Search PDQ
NIH ClinicalTrials.gov Open Studies | Exclude Unknown | "Ovarian Neoplasms" with RSS feed link

Map of NCCN Member Institutions
- Stanford Clinical Trials (out of date), Ovarian/Peritoneal/Fallopian Cancer, Gynecologic Cancers, Solid Tumor, Gynecology Clinical Research Group Eligibility Flowcharts
, Phase 1 Clinical Research Program, Liquid biopsy 
- UCSF Gynecologic Oncology Clinical Trials including upcoming, ovarian cancer list, solid tumors list, flow-chart, UCSF clinical trials, ovary search result, UCSF 500, Liquid biopsy
- UCSF Clinical Research Support Office Early Phase Clinical Trials Unit, Clinical and Translational Science Institute Early-Phase Clinical Trails Unit, Hematology and Oncology Research Earch Phase Initiative, Lab
- CPMC PAMF California Pacific Medical Center Gynecologic Cancer Clinical Trials
- UCLA
- City of Hope
- USC

Coalition of Cancer Cooperative Groups (Cancer Trials Help) Trial Screening Questionnaire, sorted by distance

EmergingMed creating profile

Cancer.net American Society of Clinical Oncology (ASCO) Finding a Clinical Trial information only

CenterWatch - Commercial clinical trials listing service institutional review board (IRB)-approved trials

NCI Cancer Trials Support Unit (CTSU) - NCI-sponsored phase III cancer treatment trials limited to some GOG, RTOG

* Alkylating antineoplastic agent - Carboplatin - crosslinking of DNA - crosslinking inhibit DNA repair and/or DNA synthesis - hypothermia enhances the effect

* Mitotic inhibitor - prevent/stop cell division - Taxane
- GOG-212 Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer PAMF
- Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial.
- History of Randomized Clinical Trials in Ovarian Cancer: Pre-Taxol Era, Taxol better for poorly-differentiated and late stage
- Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer resistance

- GOG-225 Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer SoCal

* HIPEC OVHIPEC info
- Surgery and Heated Chemotherapy for Adrenocortical Carcinoma NIH HC 4/12/2013
- ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis M S-K 3/13/2013-
+ Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer M S-K 1/10/2013
+ A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers Columbia 7/10/2012
- Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix MD A 4/17/2012-
- Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor MD A 1/12/2011

- Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer 2007 Phase III Netherlands
- Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment 2011 hase III France

- UC Irvine, Robert Bristow, Alessio Pigazzi, Kristine Penner
- UCSD, Andrew Lowy, Joel Baumgartner, Kaitlyn Kelly
Sharp, Robert Barone
Loma Linda, Maheswari Senthil

* Whole-body Hyperthermia
- Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors (FR-WB-TT/che) UT HSC 9/13/2005
- Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer UT HSC 5/14/2004
- Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer UT HSC 12/10/1999
- Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer UTH 11/1/1999

* Recurring platinum sensitive
California Trials search 
Califronia ovarian platinum Trials search, California Ovarian Recurrent search clinicaltrials.gov
* A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3), double blinded, Phase III, UCSF, PARP inhibitor
- Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer, phase I, Stanford
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2), Part 2 for 3 prior chemo only, Phase II, UCSF, gBRCA
- Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED) suspended, Phase III, Stanford, UCSF anti-folic

* Resistant, Refractory
closed Virus
** - Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies (BYL719 Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor), Phase Ib, UCSF
** - Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours Phase I, measurable, Wee1 p53 tp53, UCSF 
** - A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Phase I, immune-resistant with taxol or platin, escalation, UCSF
* - Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Phase I, Flt3 mutation, CSF-1R inhibitor, with taxol, 2cm, UCSF  
* - A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors Phase I, RAS MAPK mutation, Cleave, UCSF
** - Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors, liquid biopsy, Stanford
* - Phase I Trial of Hu5F9-G4, anti CD47 gene, escalation Stanford 

Wee1: MK1775 3/26/2008, AZD1775 12/02/2012 PO
Chk1: Eli Lilly Prexasertib (LY2606368) IV NIH 4/28/2010
P53  Elephants' Cancer-Crushing Secrets May Someday Help People
Progress in p53-targeted drugs for ovarian cancer
Critical Outcomes Technologies Looks to Enter Clinical Race for p53 Drug to Treat Cancer
1.  Cellceutix Corp CTIX Kevetrin (thioureidobutyronitrile), News, trials IV 8/2/2012 
2.  Aprea APR-246, trials IV 3/19/2014
3.  Critical Outcome Technologies, Inc COT COTI-2, COTI2 vs Kevetrin, News, trials PO, MDA, NWU, 4/27/2015

* Anti Cancer Stem Cell CSC
Novogen: Cantrixil News

Other:
- CT Antigen TCR-redirected T Cells for Ovarian Cancer Phase I-II, HLA A2 tissue type, Stanford
- A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Phase I, ROS1/ALK mutation, escalation, Stanford
- NCI-Match, Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas, 5/31/2016 Phase II, PTEN with PI3K, Stanford, PAMF, CPMC Afatinib, AZD9291 Crizofinib Dabrafenib Trastuzumab Defactinib Sunitinib, NCORP November 2015 Update, Lots of Enthusiasm in Initial Months
- A Phase 1/2 Study to Evaluate MEDI4736 Phase I-II, Stanford lung
- Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Phase I, failed standard treatments, Stanford not recruiting
- Study of ABT-165 in Subjects With Advanced Solid Tumors Phase I, UCD, Stanford breast
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies napabucasin Stemness Inhibitor Phase I, USC
- A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers Phase I, LA
- Phase 1 Study of CM-24 (MK-6018) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Phase I, LA
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) Phase II, UCSF for lung
- LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Phase II, not in UCD
- A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037) Phase II, UCD phase II for Bladder/Urothelial Cancer
- A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens Phase II, PARP-inhibitor, *Stanford*, CPMC-SF* 
- Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR), ASCO (Michigan, Carolinas), Launched: Two of the Biggest Trials Yet for Precision Medicine
- A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer (PISH-2) Phase I, Lilja, verthermia

- Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (HIPEC/IPHC) Phase II, CDDP, Lilja, BAGO

- PD-L1 Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), also search PDL1, PD-1, PD1, PD-L2, PDL2
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer (PemCiGem) phase 2, Cedar Sini
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 phase 1, Santa Monica
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) Phase 2, LA

- Cediranib Maleate and Olaparib 1-prior PAMF
- A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Phase I,II, up to 5 prior, Stanford
- Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (CORAIL) Phase III, PFI 1-6 months, no more 3, Stanford- Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer 3 prior including PARP, suspended, Phase II, antibody, CPMC-SF
- Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (CORAIL), random Topotecan, 3 prior, PFI at least 1 month, Phase III, PAMF, CPMC-SF
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2), PARP Part 2 for 3 prior chemo only, Phase II, UCSF, Stanford
- Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer MET-inhibitor, clear cell, Phase II, PAMF
- Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer clear cell Phase II, PAMF, CPMC
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers closed Phase I, Stanford, immunotherapy
- GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Phase I, II, UCSF, not BRAF mutant
+ Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer closed Reolysin (oncolytic reovirus) PAMF
- Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer only 1 prior chemo, Phase II, John Muir Health, Concord
- Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer clear cell, Phase II, BAF250a, UCSF, CPMC, PAMF

* Gemzar 1000mg/m^2 day1,8 + Carboplatin AUC 4 (Cisplatin 75mg/m^2) day 1 + Bevacizumab 15mg day 1 (A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)) Guidelines for Hospitalization for Chemotherapy outpatient
- 6-month chemo-free 
.. PAMF trial

Metformin Hydrochloride Metformin is anti-diabetic medication to treat diabetes mellitus
- Metformin against Cancer Stem Cells through the Modulation of Energy Metabolism: Special Considerations on Ovarian Cancer - Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?

- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

- Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature
- Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule
- A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy 9/4/2012 San Francisco

IDO is an enzyme which causes deplition of tryptophan which causes halted growth of T-cells
How Our Immune System Can Help Fight Cancer (ovarian)
1. Incyte IDO1 A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy, A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma (not active A Dose-escalation Study in Subjects With Advanced Malignancies phase I)
2. IDO pathway inhibitor NewLink Genetics active: Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer, (terminated DO Inhibitor Study for Relapsed or Refractory Solid Tumors (D-1MT) phase I, paper Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer)

Late-stage ovarian cancer Novel treatment strategies have yielded several promising agents that have reached phase III
New perspectives on targeted therapy in ovarian cancer 2/2015

*Angiogenesis inhibitor
Bevacizumab 4/6/2000
-- Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer - targeting extracellular receptors by the antibody aflibercept or the peptibody trebananib, the multikinase inhibitors pazopanib, nintedanib, cediranib, sunitinib, and sorafenib 
-- Angiogenesis Foundation, videos
-- Angiogenesis-Targeting Agents Poised to Become a Mainstay of Gynecologic Cancer Treatment OncLive list of clinical trials
- TRINOVA-2: Trebananib in Ovarian Cancer-2 with PLD, Phase III, San Francisco SF
- GOG-0213 with Gemcitabine
- nintedanib BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
- A clinical experience of single agent bevacizumab in relapsing ovarian cancer 2013 The PFS tended to be better in patients who experienced grade 3-4 arterial hypertension during the first month of treatment (median: 10ms) compared to patients who did not (median: 3ms)
- Targeted anti-vascular therapies for ovarian cancer: current evidence 2013 Bevacizumab beyond progression
- Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer 2014 OCEANS trial
* Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer 2014
-1 Ovarian Cancer Subtypes May Predict Response to Bevacizumab - Prognostically relevant gene signatures of high-grade serous ovarian carcinoma - (proliferative, mesenchymal) > (immunoreactive, differentiated [CA125])  - Nature: Integrated genomic analyses of ovarian carcinoma
-2 Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab - AADx assay (Almac Group Ltd) - 3 subgroups (pro-angiogenic subgroups > immune response)
-A Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy (Bevacizumab)
- bevacizumab and hypertension avastin
- Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
- Treatment of bevacizumab-induced hypertension by amlodipine
- Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- Achieving better blood pressure control
- Isolated Diastolic Hypertension 2007, Isolated Diastolic Hypertension 1995 (no systolic hypertension)
- Seeking Alpha: Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against?

* PARP inhibitor for BRCA, PTEN
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Phase 2, UCSF
- Olaparib BRCA with chemo since 6/27/2007, Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1) phase 3, finished

* Trabectedin + Doxil

* Immunotherapy Vaccine
- Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy Phase II, III with mucin 1 gene, Stanford
- Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer Oregon
- Phase Ib Trial of Folate Binding Protein Vaccine in Ovarian Cancer Ease Coast
- Ovarian Cancer Vaccine for Patients in Remission Phase II, closed

* Antifolate
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED) Phase III, Stanford, SF, suspended
Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer Phase II, NY

* Palliative
UHC
ECH, Palliative Care
PAMF, Palliative Care
Stanford Cancer Center Palliative Medicine Clinic
UCSF cancer symptom management
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options 2013

腹部腫脹, 食慾不振, 無法排便: 談婦癌病患的腸阻塞問題 bowel obstructionOvarian cancer Palliative care
** Pharmacologic Pearls for End-of-Life Care Morphine, Lorazepam, Compazine, Octreotide 0.3mg/day (papers), Levsin
* Malignant Bowel Obstruction Guide, bowel obstruction, edema, ascites, constipation: total parenteral nutrition TPN, gastrostomy, octreotide
* Fraser Health Hospice Palliative Care Symptom Guidelines for Nausea and Vomiting, dopamine D2, (Prochlorperazine [Compazine]) , 5-HT3 Ondansetron, Zophran, Hyoscyamine (Levsin)
Doctor, Does This Mean I'm Going to Starve to Death?
Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement
Palliative care in patients with ovarian cancer and bowel obstruction
Parenteral Nutrition in Malignant Bowel Obstruction: An Ethical Dilemma in Palliative Care
Gastrointestinal Complications
Palliative surgery for intestinal obstruction due to recurrent ovarian cancer
How Do You Triage Abdominal Pain in a Patient With Ovarian Cancer? small bowel obstruction SBO

Death Signs
** Bedside clinical signs associated with impending death in patients with advanced cancer: Preliminary findings of a prospective, longitudinal cohort study nonreactive pupils, a decreased response to verbal stimuli, a decreased response to visual stimuli, an inability to close eyelids, drooping of the nasolabial fold, hyperextension of the neck, grunting of vocal cords, and upper gastrointestinal bleeding
*台灣文化中末期癌症病人臨終症狀之探討 Clinical signs and symptoms on end-of-life for terminally ill cancer patients in Taiwanese culture, 臨終症狀發生率由高至低依序為：發紺冰冷（98.3%），至死亡日平均3.4天；鏡面舌（93.4%），至死亡日平均8.5天；耳垂縮（93.4%），至死亡日平均5.6天；陳氏呼吸（91.7%），至死亡日平均0.53天；煩躁不安（78.5%），至死亡日平均7.7天；死前嘎嘎聲（Death rattle）（65.2%），至死亡日平均0.89天；陰莖（囊）縮（54.4％），至死亡日平均10.1天；末期躁動（37.1%），至死亡日平均9.9天；鞏膜水腫（33.1%），至死亡日平均10.1天；譫妄（28.9%），至死亡日平均9.4天；夢到過世親人（11.5%），至死亡日平均11.4天。
*Predicting Active Dying The median time until death following the death rattle was 57 (+ or - 23, SD) hours, 7.6 (2.5) hours following respiration with mandibular movement, 5.1 (1.0) hours following cyanosis, and 2.6 (1.0) hour following lack of radial pulse. 

* Radiation Therapy
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy Phase II, UCSF
Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer Phase II, Germany

* Topoisomerase inhibitor
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma Texas, NM

* BRCA
BRCA2 >> (BRCA1,none)
The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes.

* Bevacizumab completed or not recruiting
GOG-218 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer 2005, 22-course maintenance
GOG-252 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer 2009 dose-dense, 16-course maintenance
GOG-241 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer (mEOC/GOG-0241) 2010, 12-course maintenance
GOG-262 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer 2010

* Vascular Disrupting Agent (VDA) presentation
Zybrestat (Fosbretabulin tromethamine trial)
Bionomics BNC105 (BNC105P trial)